Inflammatory Arthritis

08:00-08:55	Round Table: Patient reported outcomes in inflammatory arthritis
Chairperson	Peter Nash, Australia
08:00	Patients reported outcomes value add to rheumatology practice Helen Benham, Australia
08:15	Role of nurse practitioner Emma Bavage, Australia
08:30	Practical application in daily practice Kathleen Tymms, Australia
08:45	Discussion

08:55-09:25

Coffee Break and Poster Viewing

09:25-10:20	Lecture: Dose adjustments in inflammatory arthritis
Chairperson	Kevin Pile, Australia
09:25	Rheumatoid arthritis Tsutomu Takeuchi, Japan
09:45	Ankylosing spondylitis/psoriatic arthritis Paul Bird, Australia
10:05	Discussion

10:25-11:20	Round Table: First treatment choice in difficult rheumatoid arthritis
Chairperson	Tsutoma Takeuchi, Japan
10:25	Tablets Mark Genovese, USA
10:45	Injection therapy Boulos Haraoui, Canada
11:05	Discussion

12:25-13:30

Lunch Break and Poster Viewing

13:30-14:25	Round Table: What are the best ways to assess therapies in inflammatory arthritis?
Chairperson	Maxime Dougados, France
13:30	Randomised trials Mark Genovese, USA
13:45	Database studies Jean-Pierre Raynauld, Canada
14:00	Australian initiatives for Cochrane and clinical trials Rachelle Buchbinder, Australia
14:15	Discussion

15:00-15:55	Debate: Management of comorbidities in inflammatory arthritis
Chairperson	Mark Genovese, USA
15:00	It is the responsibility of the family physician Kevin Pile, Australia
15:20	Rheumatologists should take the lead Boulos Haraoui, Canada
15:40	Discussion

09:05-10:00	Debate: Should spondyloarthritis (SpA) be considered one single entity or should it be split into multiple diseases?
Chairperson	Huji Xu, China
09:05	Pro (one entity) Maxime Dougados, France
09:25	Con (multiple diseases) Peter Nash, Australia
09:45	Discussion

10:05-11:00	Debate: Biologic choice in psoriatic arthritis/spondylarthropathies
Chairperson	Philip Conaghan, UK
10:05	If not anti-IL-17, how do the alternatives stack up? Matt Brown, Australia
10:25	IL17 blockade should be the first choice in PSA/SA Peter Nash, Australia
10:45	Discussion

11:00-11:30

Coffee Break and Poster Viewing

11:30-12:25	Round Table: Non-radiographic ankylosing spondylitis
Chairperson	Paul Bird, Australia
11:30	Epidemiology, prevalence and diagnosis Maxime Dougados, France
11:50	Management and progression/prognosis Matt Brown, Australia
12:10	Discussion

13:30-14:30

Lunch Break and Poster Viewing

14:30-15:25	Lecture: Practical approach to the extra-articular manifestations of rheumatoid arthritis
Chairperson	Susanna M. Proudman, Australia
14:30	Interstitial lung disease Tsutomu Takeuchi, Japan
14:45	Sjögren’s Maureen Rischmeuller, Australia
15:00	Vasculitis Stephen Hall, Australia
15:15	Discussion

15:25-15:45

Coffee Break and Poster Viewing

15:45-16:40	Lecture/Round Table: Seronegative rheumatoid arthritis
Chairperson	Stephen Hall, Australia
15:45	Is sero-negative rheumatoid arthritis a different entity: Epidemiology, clinical features? Tore K. Kvien, Norway
16:05	Prognosis and management Susanna M. Proudman, Australia
16:25	Discussion

16:45-17:15	IA Oral Abstract and Award Presentations
Chairperson	Boulos Haraoui, Canada
16:45	Tele-rheumatology in South East Queensland: Evaluating a new model of care and investigation of patient perspectives Swapna Devadula, Australia
16:55	Real world considerations for the use of biosimilars in rheumatology: What do Australian physicians think? Michael Reilly, USA
17:05	Development and evaluation of topical liposomal formulation of diflunisal based on AKBA-phospholipid complex for synergistic and promising efficacy in arthritic conditions Amanpreet Kaur, India